Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas

ecancermedicalscience

Volumn 9, Issue , 2015, Pages

  Braghiroli, Maria Ignez ^a   De Celis Ferrari, Anezka C R ^a   Pfiffer, Tulio Eduardo ^a   Alex, Alexandra Kichfy ^a   Nebuloni, Daniela ^a   Carneiro, Allyne S ^a   Caparelli, Fernanda ^a   Senna, Luiz ^a   Lobo, Juliana ^a   Hoff, Paulo Marcelo ^a   Riechelmann, Rachel P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Metformin; Pancreas adenocarcinoma

Indexed keywords

BILIRUBIN; GEMCITABINE; METFORMIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER FATIGUE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSPEPSIA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT;

EID: 84955256688     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2015.563     Document Type: Article

References (20)

1. Conroy T et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med (2011) 364(19) 1817-25 DOI: 10.1056/NEJMoa1011923 PMID: 21561347
2. Oettle H et al (2014) Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial J Clin Oncol 32(23) 2423-9 DOI: 10.1200/JCO.2013.53.6995 PMID: 24982456
3. Von Hoff D et al ed (2014) NAPOLI-1 Randomized phase 3 study of mm-398 (nal-iri), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy. ESMO 16th World Congress on Gastrointestinal Cancer Barcelona Spain Ann Oncol DOI: 10.1093/annonc/mdu193.3
4. Yin M et al (2013) Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis Oncologist 18(12) 1248-55 DOI: 10.1634/theoncologist.2013-0111 PMID: 24258613 PMCID: 3868417
5. Cusi K, Consoli A and DeFronzo RA (1996) Metabolic effects of metformin on glucose and lactate metabolism in noninsulindependent diabetes mellitus J Clin Endocrinol Metab 81(11) 4059-67 PMID: 8923861
6. Dowling RJ et al (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res 67(22) 10804-12 DOI: 10.1158/0008-5472.CAN-07-2310 PMID: 18006825
7. Nair V et al (2013) Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors Carcinogenesis 34(12) 2870-9 DOI: 10.1093/carcin/bgt231 PMID: 23803693 PMCID: 3845888
8. Karnevi E et al (2012) Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells BMC Cancer 13 235 DOI: 10.1186/1471-2407-13-235
9. Kisfalvi K et al (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth Cancer Res 69(16) 6539-45 DOI: 10.1158/0008-5472.CAN-09-0418 PMID: 19679549 PMCID: 2753241
10. Zhang P et al (2013) Association of metformin use with cancer incidence and mortality: A meta-analysis Cancer Epidemiol 37(3) 207-18 DOI: 10.1016/j.canep.2012.12.009 PMID: 23352629
11. Sadeghi N et al (2012) Metformin use is associated with better survival of diabetic patients with pancreatic cancer Clin Cancer Res 18(10) 2905-12 DOI: 10.1158/1078-0432.CCR-11-2994 PMID: 22465831 PMCID: 3381457
12. Hanna RK et al (2012) Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway Gynecol Oncol 125(2) 458-69 DOI: 10.1016/j.ygyno.2012.01.009 PMID: 22252099 PMCID: 3322276
13. Rocha GZ et al (2011) Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth Clin Cancer Res 17(12) 3993-4005 DOI: 10.1158/1078-0432.CCR-10-2243 PMID: 21543517
14. Rahma OE et al (2013) Second-line treatment in advanced pancreatic cancer: A comprehensive analysis of published clinical trials Ann Oncol 24(8) 1972-9 DOI: 10.1093/annonc/mdt166 PMID: 23670093 PMCID: 3718508
15. Von Hoff DD et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N Engl J Med 369(18) 1691-703 DOI: 10.1056/NEJMoa1304369 PMID: 24131140
16. Katopodis O et al (2011) Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: The final results of a phase II trial Cancer Chemother Pharmacol 67(2) 361-8 DOI: 10.1007/s00280-010-1329-6
17. Hosein PJ et al (2013) A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer Am J Clin Oncol 36(2) 151-6 DOI: 10.1097/COC.0b013e3182436e8c
18. Wilmink J et al ed (2014) A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer ASCO Annual Meeting Chicago J Clin Oncol
19. Lonardo E et al (2013) Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells PLoS One 8(10) e76518 DOI: 10.1371/journal.pone.0076518 PMID: 24204632 PMCID: 3799760
20. Jiao Y et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331(6021) 1199-203 DOI: 10.1126/science.1200609 PMID: 21252315 PMCID: 3144496